On 11 November 2015, orphan designation (EU/3/15/1575) was granted by the European Commission to Enpharma Ltd, United Kingdom, for humanised fusion protein consisting of extracellular domain of CD24 linked to IgG1 Fc domain for the prevention of graft-versus-host disease.
The sponsor's address was updated in May 2018.
The sponsor’s address was updated in October 2020.
The sponsorship was transferred to Enpharma Europe Limited, Ireland, in November 2020.
EU/3/15/1575: Public summary of opinion on orphan designation: Humanised fusion protein consisting of extracellular domain of CD24 linked to IgG1 Fc domain for the prevention of graft-versus-host disease (PDF/125.75 KB)
First published: 06/01/2016
Last updated: 06/01/2016
humanised fusion protein consisting of extracellular domain of CD24 linked to IgG1 Fc domain
|Disease / condition||
Prevention of graft-versus-host disease
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.